Earnings ·
GeneDx Holdings Corp. reported second quarter 2026 financial results for the period ending June 30, 2026
WGSWWGeneDx Holdings Corp.
GeneDx Holdings Corp. reported second quarter 2026 financial results for the period ending June 30, 2026. Revenue increased 11% year-over-year to $114.4 million, driven by a 17% rise in exome and genome test revenue to $100.3 million and a 32% increase in volume to 30,785 tests. The company reported an adjusted net income of $0.4 million and reaffirmed its full year 2026 revenue guidance of $475 to $490 million. Concurrently, GeneDx amended its loan agreement with Blackstone to add a $50.0 million term loan facility, increasing the aggregate available principal to $150.0 million. An affiliate of Blackstone also agreed to purchase approximately $5.0 million of Class A common stock at $61.00 per share in a private placement. GeneDx operates in the genomic diagnostics industry, providing rare disease diagnosis and health insights through exome and genome testing.